Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p54
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 54/66)
Character Range: 167897–173223

(ii) an oncologist; or
                                                      Must be treated by a medical practitioner working under the direct supervision of one of the above mentioned specialist types within a hospital setting; AND
                                                      The condition must be causing intractable symptoms; AND
                                                      Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents; AND
                                                      Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND
                                                      The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days.
                                                      Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.
C16063  P16063  CN16063  Tirofiban                    Non-Q-wave myocardial infarction                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 16063
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16067  P16067  CN16067  Cefepime                     Febrile neutropenia                                                                                                                                                                                                                                                                                                                                                                                                 Compliance with Authority Required procedures
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16072  P16072  CN16072  Posaconazole                 Invasive aspergillosis                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures
                                                      Patient must be unable to tolerate alternative therapy; or
                                                      Patient must have disease refractory to alternative therapy; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16073  P16073  CN16073  Itraconazole                 Oropharyngeal candidiasis                                                                                                                                                                                                                                                                                                                                                                                           Compliance with Authority Required procedures - Streamlined Authority Code 16073
                                                      Patient must be immunosuppressed; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16075  P16075  CN16075  Rifampicin                   Meningococcal disease
                                                      The treatment must be for prophylaxis; AND
                                                      Patient must be a